Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan
- 358 Downloads
Preventive effect of stimulants on the risk of brain injuries had been reported. The aim of this study is to determine the extent to which methylphenidate (MPH) prescription moderates the risk of traumatic brain injuries (TBI) in individuals with attention-deficit/hyperactivity disorder (ADHD). Individuals with a recent diagnosis of ADHD between January 1997 and December 2013 (n = 163,618) were identified from Taiwan’s National Health Insurance Research Database. A total of 124,438 adolescents and children with ADHD and without prior TBI diagnoses were included and evaluated for subsequent TBI. Methylphenidate prescription duration was subgrouped by the annual average cumulative defined daily dose (DDD): 0, >0 to ≤28, > 28 to ≤84, and >84. We identified 11,463 diagnoses of TBI among 124,438 adolescents and children with ADHD. A Cox regression model was used to investigate whether MPH prescription influenced the risk for TBI after adjusting for sex, age, level of urbanization, seizure, autism and sedative–anxiolytics use. A reduced TBI incidence was observed with MPH prescription DDDs > 84. The protective effect of MPH against TBI persisted after adjusting for confounding factors [hazard ratio (HR) = 0.49; 95% confidence interval (CI): 0.47–0.51]. There was also statistically significant difference in risk for TBI in subjects receiving > 0 to ≤28 or >28 to ≤84 DDDs of MPH treatment (HR = 0.88, 95% CI = 0.83–0.92; HR = 0.76, 95% CI = 0.72–0.80, respectively) when compared with subjects not receiving treatment with MPH. Treatment with MPH for greater than 84 DDDs reduced the risk for TBI among children with ADHD.
KeywordsAttention-deficit/hyperactivity disorder Traumatic brain injury Methylphenidate
Attention-deficit hyperactivity disorder
National Health Insurance
Traumatic brain injury
The present study was supported in part by the Ministry of Science and Technology, R.O.C. (MOST 102-2314-B-040-004-MY3) and Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital (CMRPG6E0261). The authors would like to thank the Center of Excellence for Chang Gung Research Datalink (CORPG6D0161) for the comments and assistance in data analysis. This study was supported by a grant from the Chang Gung Memorial Hospital, Chia-yi Branch, and based on the National Health Insurance Research Database provided by the Central Bureau of National Health Insurance, the Department of Health, and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes.
Dr. Liao and Dr. Chen had the original idea for the study, designed the study, and drafted and revised the manuscript. Dr. Yang, Dr. Kuo, Dr. Huang, and Dr. Wang extracted and analyzed the data from the database. Dr. Liang, Dr. Lee, and Dr. McIntyre provided critical revision of the manuscript. Dr. Chen reviewed the literature, interpreted the analyzed data, drafted and revised the manuscript, and approved the final manuscript as submitted.
Compliance with ethical standards
The present study is supported in part by the Ministry of Science and Technology, R.O.C. (MOST 102-2314-B-040-004-MY3) and the Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital (CMRPG6E0261). All funding sources had no role in the study design, data collection, and analysis.
Conflict of interest
Author Vincent Chin-Hung Chen has received speaking honoraria from Pfizer, Eli Lilly, Janssen, Astellas, GlaxoSmithKline ,and AstraZeneca, and has been an investigator in two clinical trials from Eli Lilly and Janssen. All other authors declare that they have no conflicts of interest.
- 2.Visser SN, Bitsko RH, Danielson ML, Perou R, Blumberg SJ (2010) Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 59:1439–1443Google Scholar
- 13.Centers for Disease C, Prevention (2011) Nonfatal traumatic brain injuries related to sports and recreation activities among persons aged ≤19 years—United States, 2001–2009. MMWR Morb Mortal Wkly Rep 60:1337–1342Google Scholar
- 19.Hong J, Novick D, Treuer T, Montgomery W, Haynes VS, Wu S, Haro JM (2013) Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia. Patient Prefer Adherence 7:987–995CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Lee MJ, Yang KC, Shyu YC, Yuan SS, Yang CJ, Lee SY, Lee TL, Wang LJ (2016) Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a Nationwide Population-Based Study in Taiwan. J Affect Disord 189:110–117CrossRefPubMedGoogle Scholar
- 30.Fredriksen M, Dahl AA, Martinsen EW, Klungsoyr O, Haavik J, Peleikis DE (2014) Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity. Eur Neuropsychopharmacol 24:1873–1884CrossRefPubMedGoogle Scholar
- 31.Setyawan J, Fridman M, Hodgkins P, Quintero J, Erder MH, Katic BJ, Harpin V (2015) Relationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspective. Atten Defic Hyperact Disord 7:75–87CrossRefPubMedGoogle Scholar
- 33.Wiguna T, Guerrero AP, Wibisono S, Sastroasmoro S (2012) Effect of 12-week administration of 20-mg long-acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school-age children in Indonesia: a study using 1H magnetic resonance spectroscopy (MRS). Clin Neuropharmacol 35:81–85CrossRefPubMedGoogle Scholar
- 34.van der Marel K, Bouet V, Meerhoff GF, Freret T, Boulouard M, Dauphin F, Klomp A, Lucassen PJ, Homberg JR, Dijkhuizen RM, Reneman L (2015) Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Neuroscience 309:243–258CrossRefPubMedGoogle Scholar
- 35.Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar Roushan Z (2013) Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 47:20–24CrossRefPubMedGoogle Scholar
- 38.Lee MJ, Yang KC, Shyu YC, Yuan SS, Yang CJ, Lee SY, Lee TL, Wang LJ (2015) Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a Nationwide Population-Based Study in Taiwan. J Affect Disord 189:110–117CrossRefPubMedGoogle Scholar